Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Humoral cross reactivity between α-synuclein and herpes simplex-1 epitope in Parkinson's disease, a triggering role in the disease?

Caggiu E, Paulus K, Arru G, Piredda R, Sechi GP, Sechi LA.

J Neuroimmunol. 2016 Feb 15;291:110-4. doi: 10.1016/j.jneuroim.2016.01.007. Epub 2016 Jan 9.

PMID:
26857504
2.

Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.

Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL.

Brain. 2005 Nov;128(Pt 11):2654-64. Epub 2005 Jul 6.

PMID:
16000336
3.

Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease.

Caggiu E, Paulus K, Galleri G, Arru G, Manetti R, Sechi GP, Sechi LA.

J Neuroimmunol. 2017 Sep 15;310:26-31. doi: 10.1016/j.jneuroim.2017.06.004. Epub 2017 Jun 15.

PMID:
28778441
4.

Stage-dependent nigral neuronal loss in incidental Lewy body and Parkinson's disease.

Dijkstra AA, Voorn P, Berendse HW, Groenewegen HJ; Netherlands Brain Bank, Rozemuller AJ, van de Berg WD.

Mov Disord. 2014 Sep;29(10):1244-51. doi: 10.1002/mds.25952. Epub 2014 Jul 3.

PMID:
24996051
5.

Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.

Shannon KM, Keshavarzian A, Mutlu E, Dodiya HB, Daian D, Jaglin JA, Kordower JH.

Mov Disord. 2012 May;27(6):709-15. doi: 10.1002/mds.23838. Epub 2011 Jul 15.

PMID:
21766334
6.

Alteration in alpha-synuclein mRNA expression in Parkinson's disease.

Kingsbury AE, Daniel SE, Sangha H, Eisen S, Lees AJ, Foster OJ.

Mov Disord. 2004 Feb;19(2):162-70.

PMID:
14978671
7.

α-synuclein aggregation reduces nigral myocyte enhancer factor-2D in idiopathic and experimental Parkinson's disease.

Chu Y, Mickiewicz AL, Kordower JH.

Neurobiol Dis. 2011 Jan;41(1):71-82. doi: 10.1016/j.nbd.2010.08.022. Epub 2010 Sep 9.

PMID:
20816781
9.

α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.

Yanamandra K, Gruden MA, Casaite V, Meskys R, Forsgren L, Morozova-Roche LA.

PLoS One. 2011 Apr 25;6(4):e18513. doi: 10.1371/journal.pone.0018513.

10.

Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease.

Neystat M, Lynch T, Przedborski S, Kholodilov N, Rzhetskaya M, Burke RE.

Mov Disord. 1999 May;14(3):417-22.

PMID:
10348463
11.

Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.

Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E.

CNS Neurosci Ther. 2014 Jan;20(1):50-8. doi: 10.1111/cns.12200. Epub 2013 Nov 27.

PMID:
24279716
12.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
13.

Alpha synuclein is present in Lewy bodies in sporadic Parkinson's disease.

Mezey E, Dehejia AM, Harta G, Tresser N, Suchy SF, Nussbaum RL, Brownstein MJ, Polymeropoulos MH.

Mol Psychiatry. 1998 Nov;3(6):493-9. Erratum in: Mol Psychiatry 1999 Mar;4(2):197.

PMID:
9857974
14.

Agrin binds alpha-synuclein and modulates alpha-synuclein fibrillation.

Liu IH, Uversky VN, Munishkina LA, Fink AL, Halfter W, Cole GJ.

Glycobiology. 2005 Dec;15(12):1320-31. Epub 2005 Jul 21.

PMID:
16037493
15.

Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.

Kovacs GG, Milenkovic IJ, Preusser M, Budka H.

Mov Disord. 2008 Aug 15;23(11):1608-12. doi: 10.1002/mds.22207.

PMID:
18649394
16.

Is there a role for Mycobacterium avium subspecies paratuberculosis in Parkinson's disease?

Arru G, Caggiu E, Paulus K, Sechi GP, Mameli G, Sechi LA.

J Neuroimmunol. 2016 Apr 15;293:86-90. doi: 10.1016/j.jneuroim.2016.02.016. Epub 2016 Feb 27.

PMID:
27049567
17.

GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease.

Decressac M, Ulusoy A, Mattsson B, Georgievska B, Romero-Ramos M, Kirik D, Björklund A.

Brain. 2011 Aug;134(Pt 8):2302-11. doi: 10.1093/brain/awr149. Epub 2011 Jun 28.

PMID:
21712347
18.

Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.

Andringa G, Lam KY, Chegary M, Wang X, Chase TN, Bennett MC.

FASEB J. 2004 May;18(7):932-4. Epub 2004 Mar 4.

PMID:
15001552
19.

Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.

Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O.

Mov Disord. 2011 Jul;26(8):1428-35. doi: 10.1002/mds.23670. Epub 2011 Apr 5.

PMID:
21469206
20.

Residual substantia nigra neuromelanin in Parkinson's disease is cross-linked to alpha-synuclein.

Fasano M, Giraudo S, Coha S, Bergamasco B, Lopiano L.

Neurochem Int. 2003 Jun;42(7):603-6.

PMID:
12590943

Supplemental Content

Support Center